Search Results

Sirtex Medical announced today the appointment of Matt Schmidt as chief executive officer and board of directors member, effective March 25.

Sirtex Medical (“Sirtex”), a leading manufacturer of interventional treatment solutions, announced today the commercial availability of the LAVA® Liquid Embolic System, the first and only liquid embolic approved for the treatment of peripheral vascular hemorrhage.

Sirtex Medical (“Sirtex”) announced today the establishment of a collaboration and exclusive worldwide distribution agreement with Magle Group, a Sweden-based contract development and manufacturing organization as well as Degradable Starch Microspheres (DSM) sales and marketing company.

Sirtex Medical (“Sirtex”), a leading manufacturer of targeted liver cancer therapies, announced that the Brazilian National Agency of Supplementary Health (ANS) approved SIR-Spheres® Y-90 resin microspheres for the treatment of intermediate and advanced stage hepatocellular carcinoma (HCC) in Brazil.

Sirtex Medical US Holdings, Inc. (“Sirtex”), a leading manufacturer of targeted cancer therapies, announced an advancement in its strategic collaboration with OncoSec Medical, Inc. (NASDAQ: ONCS) relating to OncoSec’s lead product candidate TAVO™ (tavokinogene telseplasmid) and its electroporation (EP) gene delivery system.

Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, announced with its shareholder, Grand Pharmaceutical Group Limited, that SIR-Spheres® Y-90 resin microspheres have been approved by the National Medical Products Administration for the treatment of patients with colorectal cancer liver metastases.

OncoSec Medical Incorporated (NASDAQ:ONCS) (the “Company” or “OncoSec”) today announced it entered into an agreement with Sirtex Medical, Inc. (Sirtex) granting Sirtex an option to non-exclusively co-promote the Company’s lead product candidate, TAVO™ (tavokinogene telseplasmid) in anti-PD-1 checkpoint refractory metastatic melanoma in the U.S.